Overview
Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer
Status:
Recruiting
Recruiting
Trial end date:
2028-01-01
2028-01-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate the efficacy of gemcitabine and nab-paclitaxel venous injection plus transcatheter arterial infusion to Patients with Advanced Pancreatic Cancer.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Fudan UniversityTreatments:
Gemcitabine
Paclitaxel
Criteria
Inclusion Criteria:- Ability to understand and the willingness to sign a written informed consent document.
- Age ≥ 18 years and ≤ 80 years.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Histologically or cytologically confirmed advanced pancreas adenocarcinoma.
- Primary pancreatic cancer without major anti-cancer treatments.
- Locally advanced, or metastatic pancreatic cancer.
- Presence of at least of one measurable lesion in agreement to RECIST criteria.
- The expected survival ≥ 3 months.
- Adequate organ performance based on laboratory blood tests.
- Patients who are willing or able to comply with study procedures.
Exclusion Criteria:
- Pregnant or nursing women.
- Patients who have received anti-tumor chemotherapy, radiotherapy, or other treatments.
- The diagnosis was confirmed by pathology as non-adenocarcinoma of pancreas.
- Inflammation of the digestive tract, including pancreatitis, cholecystitis,
cholangitis, etc.
- Severe and uncontrollable accompanying diseases that may affect protocol compliance or
interfere with the interpretation of results.
- Cardiovascular and cerebrovascular accidents.
- Allergic to study drugs.
- Other serious accompanying illnesses, which, in the researcher's opinion, could
seriously adversely affect the safety of the treatment.